tbuckley/cabot-search huggingface dataset:
A More Intensive Regimen of Albumin Dyalisis Improves Survival in Patients with Acute on Chronic Liver Failure. Results from an Individual-Patient Data Meta-Analysis
Authors: L.I. Samaniego, C. Olmedo, M. Pavesi, J. Torner, M.-V. Catalina, T. Hassanein, U. Heemann, F. Nevens, F. Larsen, R. Jalan, A. Albulos, H. Schmidt, R. Moreau, V. Arroyo, R. Bañares
Journal: Journal of Hepatology (2016)
Metabolic Pathway Reprogramming by CRISPR/CAS9 Genome Editing
Authors: F. Pankowicz, M. Barzi, J. Tomolonis, B. Bissig-Choisat, X. Legras, M. Ravishankar, Q. Sun, M. Borowiak, S.H. Elsea, P. Sumazin, K.-D. Bissig
Journal: Journal of Hepatology (2016)
Subjective Cognitive Decline in Preclinical Alzheimer's Disease
Authors: Laura A. Rabin, Colette M. Smart, Rebecca E. Amariglio
Journal: Annual Review of Clinical Psychology (2017)

Older adults with subjective cognitive decline (SCD) in the absence of objective neuropsychological dysfunction are increasingly viewed as at risk for non-normative cognitive decline and eventual progression to Alzheimer's disease (AD) dementia. The past decade has witnessed tremendous growth in research on SCD, which may reflect the recognition of SCD as the earliest symptomatic manifestation of AD. Yet methodological challenges associated with establishing common assessment and classification procedures hamper the construct. This article reviews essential features of SCD associated with preclinical AD and current measurement approaches, highlighting challenges in harmonizing study findings across settings. We consider the relation of SCD to important variables and outcomes (e.g., AD biomarkers, clinical progression). We also examine the role of self- and informant-reports in SCD and various psychological, medical, and demographic factors that influence the self-report of cognition. We conclude with a discussion of intervention strategies for SCD, ethical considerations, and future research priorities.
Transcriptional Networks Controlled by NKX2-1 in the Development of Forebrain GABAergic Neurons
Authors: Magnus Sandberg, Pierre Flandin, Shanni Silberberg, Linda Su-Feher, James D. Price, Jia Sheng Hu, Carol Kim, Axel Visel, Alex S. Nord, John L.R. Rubenstein
Journal: Neuron (2016)
Allogeneic vs autologous stem cell transplantation according to cytogenetic features in AML patients (pts) <= 45 yrs old in first CR: Results of the EORTC-GIMEMA AML-10 trial
Authors: S Suciu, R Zittoun, F Mandelli, T de Witte, E Gallo, A Belhabri, B Labar, B Rotoli, E Cacciola, B Varet, Liso, F Ferrara, U Jehn, S Mirto, JH Bourhis, S Amadori, P Fazi, P Rodts, Anne Hagemeijer-Hausman, R Willemze
Journal: Blood (2001)
Abstract 10404: Incidence and Predictors of Asymptomatic Pericardial Effusion After Transcatheter Closure of Atrial Septal Defect
Authors: Jingjin Wang, Mehul Patel, Minghu Xiao, Zhongying Xu, Shiliang Jiang, Hao Wang
Journal: Circulation (2015)

Introduction: Pericardial effusion (PE) without obvious periprocedural complications (e.g., cardiac perforation, device erosion) may occur after transcatheter closure of secundum atrial septal defects (ASD).It has only been described in case reports, and has not been the subject of systematic study. Hypothesis: The aim of the study is to investigate the incidence and predictors of PE unrelated to procedural complications, thus providing interventional cardiologists with a novel way to approach new-onset PE after ASD closure. Methods: We included all patients who had undergone successful percutaneous ASD closure from June 2009 to April 2014 (n=2652) with no preexisting PE or cardiac perforation or erosion. Transthoracic echocardiography (TTE) was performed during the procedure and 1, 3, and 6 months postoperatively. Results: After device implantation, fifty patients (1.9 %) developed new-onset PE (37 immediately, 13 during follow-up). These patients were asymptomatic, stable hemodynamically, and had no new arrhythmias. PE appeared mild (5.1±1.9 mm) and homogeneously echo-lucent by TTE (Figure). PE diminished spontaneously. Compared with 2602 patients without PE, factors independently predicting asymptomatic PE were the device touching the atrial free wall, device size, patient age, and total defect size (Table). Areas under the receiver operating characteristic curves were 0.78 (p&lt;0.001), 0.66 (p&lt;0.001) and 0.77 (p&lt;0.001) for device size, patient age, and total defect size, respectively. Conclusion: A new type of PE is firstly reported systematically. Our data provide new insights into new-onset PE after percutaneous ASD closure.
Deciphering Epigenetic Reprogramming in Persistent Hepatitis C Virus Infection Reveals Candidate Drivers of Hepatocarcinogenesis
Authors: S. Bandiera, N. Hamdane, I. Davidson, C. Thumann, M.B. Zeisel, Y. Hoshida, N. Bardeesy, T.F. Baumert
Journal: Journal of Hepatology (2016)
The Sodium Taurocholate Co-Transporting Polypeptide (NTCP) Facilitates HCV Entry by Modulating Bile Acid Transport and Expression of Interferon-Stimulated Genes
Authors: E.R. Verrier, C.C. Colpitts, L. Zona, C. Batch, L. Heydmann, R.G. Tawar, C. Thumann, C. Schuster, C. Sureau, Y. Hoshida, M.B. Zeisel, T.F. Baumert
Journal: Journal of Hepatology (2016)
Recombinant Factor VIII Combined With Recombinant Von Willebrand Factor In Patients With Severe Hemophilia A: A Prospective Clinical Study Of Safety and Pharmacokinetics
Authors: Toshko Lissitchkov, Jerzy Windyga, Barbara A. Konkle, Wolfgang Draxler, Miranda Chapman, Wing-Yen Wong, Benny Sørensen, Bruce M. Ewenstein
Journal: Blood (2013)
Nilotinib for patients with advanced GIST who failed imatinib and sunitinib: Negative effect of prior major gastrectomy on exposure to nilotinib.
Authors: K. Kim, M. Ryu, C. Yoo, B. Ryoo, D. Choi, H. Chang, J. Lee, T. Kim, M. Beck, Y. Kang
Journal: Journal of Clinical Oncology (2010)

10016 Background: Nilotinib, a novel tyrosine kinase inhibitor (TKI), has been suggested to be active for advanced gastrointestinal stromal tumors (GISTs). Drug-food interaction studies on the bioavailability of nilotinib suggest the importance of the stomach in nilotinib absorption. Methods: We analyzed the efficacy, tolerability and PK parameters of nilotinib (400 mg twice daily) in 17 consecutive patients who had advanced GISTs resistant to both imatinib and sunitinib treated with nilotinib in Compassionate Use Program at the Asan Medical Center, Seoul, Korea between May 2007 and October 2009. Results: The median age was 59 years (range 35-71). Most of the patients were male (82.4%). Mean body weight was 59.4 kg. Among the total 17 patients, one (5.9%) had partial response (PR), 12 (70.6%) had stable disease (SD), and 4 (23.5%) had progressive disease (PD), according to RECIST criteria. Clinical benefit rate (CR+PR+SD) at 24 weeks was 47.1%. The median progression-free survival (PFS) and overall survival (OS) were 47.1 weeks (95% confidence interval 5.6≂̃f88.7 weeks) and 74.0 weeks (95% confidence interval 8.7∼139.3 weeks), respectively. Observed adverse events were mostly mild (grade 1, 41.2%; grade 2, 52.9%) with no grade 3/4 adverse events. PK parameters of nilotinib (n=17) were as follows: Cmax, 1,754 ± 970 mg/L; T1/2, 13.4 ± 8.94 hr; and AUC0–24hr, 14,189 ± 6,853 hr*mg/L. The AUC0–24hr of nilotinib was significantly lower in patients with prior major gastrectomy (total or subtotal gastrectomy; n=4; 8526±7869 hr*mg/L) than in patients without prior major gastrectomy (n=13; 15930±5759 hr*mg/L; p=0.014). Among the 4 gastrectomized patients, two patients (50%) showed markedly decreased nilotinib exposure (AUC0-24hr of 1914, 3194 hr*mg/L) and rapid disease progression (PFS of 4.6, 7.1 weeks). Conclusions: Nilotinib was active and safe in patients with advanced GIST resistant to both imatinib and sunitinib. Prior gastrectomy seemed to decrease the bioavailability of nilotinib significantly at least in some patients. Monitoring of plasma drug concentration may be particularly important for proper nilotinib therapy in GIST patients with major gastrectomy. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis, Pfizer Novartis, Pfizer
Clinical assessment and management of multimorbidity: summary of NICE guidance
Authors: Caroline Farmer, Elisabetta Fenu, Norma O’Flynn, Bruce Guthrie
Journal: BMJ (2016)

#### What you need to know

For those with multimorbidity

Most people with a chronic condition have one or more other chronic conditions, and multimorbidity is the norm in older people (see infographic 1 and box1).1 Multimorbidity matters because it is associated with reduced quality of life, higher mortality, polypharmacy and higher rates of adverse drug events, and high use of unplanned health care.2 3 4 5 Those with multimorbidity frequently receive care from both primary care and multiple specialists, who may not be communicating effectively with each other.6 7 Clinicians express uncertainty about the balance of benefit and harm of treatments in people with multimorbidity because evidence is largely based on trials of interventions for single conditions, from which people with multimorbidity are often excluded.8 9 Guidelines derived from such trials may lead to burdensome levels of treatment or unfeasible patterns of healthcare use .10

#### Box 1: What is multimorbidity?

Multimorbidityis the presence of two or more long term health conditions, which can include:

There is increasing recognition that care for some people with multimorbidity needs reorganisation,11 12 13 14 although not everyone with multimorbidity will require additional support. This guideline is intended to provide guidance on the optimum management of people with multimorbidity who need an approach to care …
LO2 : Significant reduction of HBsAg and HDV RNA by the nucleic acid polymer REP 2139 in caucasian patients with chronic HBV/HDV co-infection
Authors: M. Bazinet, V. Pantea, V. Cebotarescu, L Cojuhari, P. Jimbei, A. Vaillant
Journal: Journal of Hepatology (2015)
Lung Toxicity after Post-Operative Radiotherapy after EPP for Mesothelioma and Pneumonectomy for Non-Small Cell Lung Cancer
Authors: Angela Botticella, Cedric Draulans, Gilles Defraene, Kristiaan Nackaerts, Christophe Deroose, Johan Coolen, Philippe Nafteux, Stéphanie Peeters, Dirk De Ruysscher
Journal: Journal of Thoracic Oncology (2015)
TREM-2 Protects the Liver from Immune-Mediated Hepatocellular Damage
Authors: M.J. Perugorria, O. Sharif, F. Oakley, A. Esparza-Baquer, A. Korosec, J. Mann, I. Labiano, D. Tiniakos, R. Gawish, R. Jiménez-Agüero, L. Bujanda, J.M. Banales, S. Knapp, D.A. Mann
Journal: Journal of Hepatology (2016)
Mental health issues need private space for discussion
Authors: Simon P Braybrook
Journal: BMJ (2016)

Armstrong discusses how social networking can help patients.1 I’m a GP with a special interest in psychiatry, and I’m a mental health patient. During my years with depression I’ve received primary and secondary medical and psychological treatment. I’m very public about it—I’ve talked frankly about using antidepressants at Healthtalkonline,2 and about stress in primary care for Mind,3 as …
Molecular Heterogeneity and Trunk Driver Mutations in Hepatocellular Carcinoma
Authors: D. Sia, A.N. Harrington, S. Torrecilla, Z. Zhang, G. Camprecios, A. Moeini, S. Toffanin, I. Fiel, K. Hao, M. Higuera, L. Cabellos, H. Cornella, M. Mahajan, Y. Hoshida, A. Villanueva, S. Florman, M. Schwartz, J.M. Llovet
Journal: Journal of Hepatology (2016)
Risk Factors and Characteristics of Hepatocellular Carcinoma Occuring in HCV Cirrhotic Patients after Sustained Virological Response
Authors: A. Payancé, N. Goutté, E. Clair, V. Paradis, M. Bouattour, M.-P. Vullierme, C. Castelnau, N. Boyer, O. Farges, T. Asselah, F. Durand, P. Bedossa, P. Marcellin, L. Castera
Journal: Journal of Hepatology (2016)
Successful Bilateral Cataract and Circumcision Operation Performed in a Hemophilia-A Patient with Inhibitors by Using Recombinant Factor VIIa.
Authors: Yurdanur Kilinc, Ilgen Sasmaz, Goksel Leblebistan, Bulent Antmen, Selcuk Sizmaz, Meltem Yagmur, Sibel Cayli
Journal: Blood (2005)
Effectiveness and Safety of DAA Combination Therapies for Treatment of HCV in Elderly Patients (&gt;70 Yrs): Results from the German Hepatitis C-Registry
Authors: T. Welzel, E. Schott, J. Petersen, S. Mauss, T. Zimmermann, K.-G. Simon, H. Hinrichsen, T. Berg, H. Pfeiffer-Vornkahl, S. Zeuzem, D. Hüppe, H. Wedemeyer, K.H.W. Böker
Journal: Journal of Hepatology (2016)
Statins prevent LV remodelling through anti-fibrotic effects associated with AMPK activation rather than direct effects on cardiomyocytes in a mouse model of metabolic syndrome
Authors: N Hermida, A Markl, J Hamelet, Paul Herijgers, S Horman, Goedele Noppe, C Beauloye, M Van Bilsen, C Dessy, J-L Balligand
Journal: Cardiovascular Research (2012)
High SVR Rates with the Combination of ABT-493 + ABT-530 for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 1 or 2 Infection
Authors: F. Poordad, F. Felizarta, S. Wang, A. Asatryan, T. Hassanein, H. Aguilar, J. Lalezari, J.S. Overcash, T.I. Ng, S.S. Lovell, C.-W. Lin, J. Kort, F.J. Mensa
Journal: Journal of Hepatology (2016)
Secondary Hyperparathyroidism Induced by Plateletpheresis in Donors As a Result of Divalent Cationic Chelation by Citrate.
Authors: Sergio Sanchez-Guerrero, Nidia Zapata-Canto, Maricruz Tolentino-Dolores, Arlette Barbosa-Ibarra, Patricia Volkow-Fernandez, Labardini Juan, Lizbeth Zamora-Sanchez, Alma Alonso-Lopez, Eloisa Rivas-Pichon, Leticia Buendia-Gomez, Delfina Damian-Yañez, Claudia Angel Ortiz, Reyna Samano-Samano, Rosa M Morales, Lourdes Schnaas
Journal: Blood (2012)
Retreatment with docetaxel in metastatic castration-resistant prostate cancer (CRPC).
Authors: A. Gernone, A. Pagliarulo, V. Pagliarulo
Journal: Journal of Clinical Oncology (2010)

e15020 Background: In 2004 docetaxel was approved and has become the standard of care in first- line for metastatic CRPC. The optimal treatment duration with docetaxel is not known and the 2nd line chemotherapy continues to be an unmet medical need. This study examines whether pts with metastatic CRPC, who initially respond to docetaxel chemotherapy, maintain their sensitivity to subsequent retreatment. Methods: 120 pts with metastatic CRPC, treated between 2003 and 2009, received 3-weekly docetaxel 75 mg/mq and 5 mg of prednisone bid. The median age was 68 (42-87), median baseline PSA: 103 ng/ml (range 6-820), median ECOG PS: 1 (range 0-2). The end points were: PSA response proportion (defined by Consensus Criteria) to first-second-third-fourth line docetaxel chemotherapy, median survival in docetaxel responding pts and duration of chemotherapy holiday. Results: Response to chemotherapy was assessed at every 3 cycles of treatment. 26/120 pts were docetaxel non-responding. 94/120 pts received first-line docetaxel chemotherapy with median no. of cycles (range) 15.5 (8-29), of these patients 66 were re-treated with the same regimen (first retreatment), on biochemical disease progression, with median no. of cycles 13.1 (3-28). A further 42 out of these 66 pts received second docetaxel re-treatment (third-line chemotherapy) with median no. of cycles 9.6 (4-25). Of these, 3/42 pts responded to third docetaxel retreatment (fourth-line chemotherapy) with median no. of cycles 5 (3-6) to date. PSA response was: 72% after first-line chemotherapy, 47% after first retreatment, 21% after second retreatment, 15% after third retreatment. Median survival was 20 mos after first-line, 16 mos after first retreatment, 13 mos after second retreatment, 6 mos after third retreatment. The duration of first chemotherapy holiday was 4.5 mos (median), the duration of second chemotherapy holiday was 4 mos (median), the duration of third chemotherapy holiday was 5 mos (median). No pts died on therapy. Conclusions: Retreatment with docetaxel was well tolerated (no discontinuation of treatment) in responding pts and was associated with high response proportions after first-line. Median survival of responding pts from the first line to the third-retreatment was approximately 55 mos. No significant financial relationships to disclose.
Computer Assisted Morphometric Analysis of Hepatic Sonic Hedgehog Expression Correlates with Circulating Markers of Cell Death and Key Histologic Features of Non-Alcoholic Steatohepatitis
Authors: M. Estep, R. Mehta, G. Bratthauer, Z. Nayer, L. Alaparthi, F. Monge, I. Ali, D. Abdelatif, Z. Younoszai, Z. Goodman, Z.M. Younossi
Journal: Journal of Hepatology (2016)
Diabetes is not Associated with an Increased Risk of Hepatocellular Carcinoma in Patients with Alcoholic, HBV or HCV Liver Cirrhosis
Authors: C.R. Escaja, C.A. Navascués, L. González-Diéguez, V. Cadahía, M. Varela, M.Á. De Jorge, M. Rodríguez
Journal: Journal of Hepatology (2016)
R-CHOP in Primary Mediastinal B-Cell Lymphoma (PMBL): Results from the UK NCRI R-CHOP 14 v 21 Trial
Authors: Mary Gleeson, Eliza A Hawkes, David Cunningham, Nick Chadwick, Nick Counsell, Anthony Lawrie, Andrew Jack, Paul Smith, Paul Mouncey, Christopher Pocock, Kirit Ardeshna, John Radford, Andrew McMillan, John Davies, Deborah Turner, Anton Kruger, Peter W.M. Johnson, Joanna Gambell, David Linch
Journal: Blood (2015)
Directors of public health are pivotal in tackling health inequalities
Authors: Michael Craig Watson, Sylvia Tilford
Journal: BMJ (2016)

The BMJ reports on plans for government policy to tackle health inequalities.1

The health select committee’s report is clear about why public health is important and the key roles the NHS has to play.2 However, many doctors and nurses will need training and time to deliver additional preventive advice.

The committee’s report also …
Kratom Products Seized
Authors: Rebecca Voelker
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Many important language universals are not reducible to processing or cognition
Authors: David P. Medeiros, Massimo Piattelli-Palmarini, Thomas G. Bever
Journal: Behavioral and Brain Sciences (2016)

Abstract Christiansen &amp; Chater (C&amp;C) ignore the many linguistic universals that cannot be reduced to processing or cognitive constraints, some of which we present. Their claim that grammar is merely acquired language processing skill cannot account for such universals. Their claim that all other universal properties are historically and culturally based is a nonsequitur about language evolution, lacking data.
Dynamic Contrast Enhanced Ultrasound Perfusion Imaging and Clinically Significant Portal Hypertension in Patients with Liver Cirrhosis: A Feasibility Study
Authors: M.E. Ainora, M. Garcovich, B.E. Annicchiarico, M. Siciliano, L. Riccardi, M. Pompili, G.L. Rapaccini, A. Gasbarrini, M.A. Zocco
Journal: Journal of Hepatology (2016)
Psychological Scars From Conflict in South Sudan Documented
Authors: M.J. Friedrich
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Synergistic apoptosis and antitumor activity induced by ST1926, an atypical retinoic acid derivative
Authors: C. Zanna, C. Pisano, L. Vesci, S. Pace, M. R. Lucreziotti, L. Merlini, F. Zunino, S. McCanna, S. Penco, P. Carminati
Journal: Journal of Clinical Oncology (2007)

14029 Background: ST1926 is a novel adamantyl retinoid active against a wide panel of human tumor cell lines, including p53-defective cells. Moreover, its cytotoxic activity is not affected by Pgp overexpression or resistance to cisplatin. The drug induces an early G 1 /S cell cycle arrest associated with a modulation of genes involved in apoptosis and DNA damage. Although the ST1926 molecular targets are still not fully elucidated, some in vitro studies suggest that this drug induces activation of both intrinsic and extrinsic apoptotic pathways. Methods: ST1926 antiproliferative activity was evaluated in vivo by oral route using fractionated daily schedules in CD1 nude mice against different human tumor xenografts, including NSCLC, ovarian carcinoma, H&amp;N, neuroblastoma and melanoma, as well as hematological malignancies. Pharmacokinetic and toxicological studies were conducted in rodents and dogs after single and repeated (5 days and 4 weeks) oral administration. Results: As monotherapy, ST1926, showing a favorable tolerability profile, was effective in inhibiting tumor growth in several tumor models. In particular, ST1926 showed significant tumor inhibition on doxorubicin- and platinum-resistant ovarian carcinomas at 30 mg/kg po given according to different schedules. The most prominent tumor growth inhibitory effects were noted in combination regimens with cisplatin and carboplatin in both sensitive and resistant ovarian carcinoma. The plasma t1/2 was about two hours in all animal species tested. The hemolymphopoietic system and GI tract were identified as the main target organs of toxicity. Toxicology findings indicated the starting dose in humans at 30 mg daily for five consecutive days. Conclusions: ST1926 is a new antitumor proapototic agent acting through particular molecular mechanisms. ST1926 is active by oral administration on both solid tumors, especially ovarian carcinoma, and acute myeloid leukemia. A Phase I clinical program to evaluate safety and tolerability of ST1926 as monotherapy and in combination with platinum compounds is ongoing in women with advanced ovarian cancer. [Table: see text]